Goldman Sachs CEO Lloyd Blankfein: I Don't Love Cryptocurrency
Goldman Sachs CEO Lloyd Blankfein says a lot of the talk about cryptocurrencies is “hype” and that he doesn’t “love” the concept of the digital assets.
“I don’t get how something that moves thirty percent in a day, or twenty percent, can be a store of value,” he told Cheddar. “Something that is very hard to clear or retain, that gets stolen a lot -- I don’t see how that can be a medium of exchange.”
His statements come after reports in December that Goldman was planning to launch a crypto trading desk by the middle of this year. Blankfein clarified that, while the company will clear futures contracts for customers, it has no plans at this time to buy, sell, and hold positions in digital assets for its customers.
Blankfein did acknowledge, though, that his skepticism over crypto may prove to be unwarranted.
“I remember when cell phones came out, and I said to myself, ‘Who the hell is going to lug around this thing?’ A lot of things have worked out that I don’t love...I’ve learned in my life in the financial markets, sponsoring companies and investing in things, to keep an open mind as long as you can.”
For full interview [click here](https://cheddar.com/videos/goldman-sachs-ceo-lloyd-blankfein-weighs-in-on-market-volatility-crypto-and-trump).
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
A labor rights group has alleged that Starbucks sourced coffee from a major Brazilian cooperative whose member farms were cited for keeping workers in slave-like conditions.
X, the social media platform owned by Trump adviser Elon Musk, is challenging the constitutionality of a Minnesota ban on using deepfakes to influence elections and harm candidates.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
